Consortium Plans to Apply Spatial Analysis to Major Challenges in
The consortium is focused on using the GeoMx Digital Spatial Profiler to address some of the most challenging translational research questions in breast cancer by applying spatial analysis. Some of the initial projects that the GBCC is planning include studies that will explore the immune interactions in HER2+ breast cancer, responsiveness to immunotherapy in triple-negative breast cancer (TNBC), disease evolution in metastatic breast cancer, and role of the tumor microenvironment in molecular epidemiological studies.
Through the work of the GBCC,
“By evaluating breast cancer with a spatial approach, we hope to expand our ability to understand the impact of treatments on the tumor, immune infiltrate and microenvironment,” said
“While earlier diagnosis and new therapies have improved patient outcomes in breast cancer, there are subgroups of patients with aggressive disease where effective therapies remain elusive,” said
Founding member institutions and investigators of the
The Dana Farber Cancer Institute: Elizabeth Mittendorf, M.D., Ph.D.
The Mayo Clinic: Jodi Carter, M.D., Ph.D.; Aubrey Thompson, Ph.D.; Fergus Couch, Ph.D.
The Peter MacCallum Cancer Centre: Sherene Loi, Ph.D.
University of North Carolina, Chapel Hill: Melissa Troester, M.P.H., Ph.D.
Georgetown University Medical Center: Sandra Swain, M.D.
The Institut d'Investigacions Biomèdiques:
August Pii Sunyer (IDIBAPS): Aleix Prat, M.D., Ph.D.
Researchers that are interested in joining the
For more information, please visit www.nanostring.com.
Vice President, Investor Relations & Corporate Communications